CN104161839A - Pharmaceutical composition for treating fatty liver, and traditional Chinese medicine preparation thereof - Google Patents
Pharmaceutical composition for treating fatty liver, and traditional Chinese medicine preparation thereof Download PDFInfo
- Publication number
- CN104161839A CN104161839A CN201410251116.2A CN201410251116A CN104161839A CN 104161839 A CN104161839 A CN 104161839A CN 201410251116 A CN201410251116 A CN 201410251116A CN 104161839 A CN104161839 A CN 104161839A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- chinese medicine
- fatty liver
- medicine preparation
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating fatty liver. Effective ingredients of the pharmaceutical composition comprise one selected from raw hawthorn, cassia seed and bushy knotweed rhizome, or a mixture of more than one of the above. A weight proportion of raw hawthorn is 3-50; a weight proportion of cassia seed is 2-50; and a weight proportion of bushy knotweed rhizome is 5-40. The invention also discloses a traditional Chinese medicine preparation containing the pharmaceutical composition. The traditional Chinese medicine preparation may be any one of medicinal tea, water decoction, granules, powder, injection, patches, ointment, tablets and pills. The traditional Chinese medicine preparation is an ancillary drug for treating the fatty liver by acupuncture and moxibustion therapy. The pharmaceutical composition provided by the invention is cheap, and has a definite therapeutic effect and good security. By combining the traditional Chinese medicine preparation and the acupuncture and moxibustion therapy to treat the fatty liver, a stable and definite curative effect can be achieved; the method is simple; and normalization is easy to form. The traditional Chinese medicine preparation is convenient for normalized implementation and popularization in various hospitals, particularly community hospitals, thereby providing cheap, convenient, simple and effective medical services for the majority of patients.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of Chinese medicine, especially design a kind of Chinese medicine composition that is used for the treatment of fatty liver disease.
Background technology
Fatty liver, refer to the pathological changes of fatty overheap in the hepatocyte causing due to a variety of causes, owing to can not carrying out normal lipid metabolism, and lipid, especially neutral fat (triglyceride) stockpiles too much in liver, observes the disease of fatty ghost in hepatocyte more than half.The positive serious threat compatriots' of fatty liver disease health, becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.Fatty liver can be subdivided into obese fatty liver, alcoholic fatty liver, dystrophic fatty liver, diabetic fatty liver, Drug fatty liver, gestational fatty liver and as infect in conjunction with, bacterial pneumonia or septicemia etc. the fatty liver causing according to the reason of morbidity.
Clinically, in more than 5% hepatocyte, implement fat or think fatty liver when fat surpasses 5mg in every 100mg liver.Along with improving constantly of people's Living Water product, the dietetic life of higher fatty acid, high heat and make Patients with Fatty Liver be the trend of rising based on the flourishing hypomotility of civilization etc., and age of onset is also day by day tending towards becoming younger.Patients with Fatty Liver mostly is obesity, and hobby is indulged in excessive drinking or had a liking for the greasy sweet fertilizer of edible oil.Chamber checks and is usually expressed as serum total cholesterol, whole blood viscosity, plasma viscosity and triglyceride all higher than normal value by experiment, in addition, also shows as liver enlargement.If fatty liver is treated not in time, be easy to be further developed into the diseases such as hepatitis, liver cirrhosis, hepatocarcinoma.
And from differential diagnosis in tcm angle, the clinical manifestation of fatty liver mostly be in phlegm-damp accumulate, stagnation of liver-QI with deficiency of the spleen, that soil is stopped up wood is strongly fragrant.
The existing technology for fatty liver treatment mainly be take Western medicine or operative treatment as main.As disclosed a kind of compositions of improving fatty liver in patent CN10259214A, described compositions contains at least one extract in Fructus Lycopersici esculenti herb extract, hemlock chervil extract and Radix Arnebiae extract, described method is by chemical method effective component extracting from Fructus Lycopersici esculenti, hemlock chervil and Radix Arnebiae (Radix Lithospermi), and after extracted composition is analyzed, the treatment for fatty liver improves.But the cost that above-mentioned method is extracted is high, difficulty is large, has limited being widely used of said medicine.
In addition, adopt the method for Western medicine or operative treatment, cannot realize the health care to human liver, easily out in the cold due to the early stage non-evident sympton of fatty liver, when there is obvious pathological changes in liver, fatty liver is generally more serious, therefore easily misses best treatment time, conditions of patients is increased the weight of or develop into liver cirrhosis, hepatocarcinoma etc.Even if find in time fatty liver, the method for the treatment of causes larger injury and medical expense costliness to Patients with Fatty Liver, and medical resource concentrates in large hospital, cannot go deep into situation of all-level hospitals, and especially community hospital, cannot allow extensive patients obtain the effective treatment.
Summary of the invention
In order to solve deficiency of the prior art, the application specifically provides a kind of pharmaceutical composition and Chinese medicine preparation thereof that can be used for treating fatty liver.
A first aspect of the present invention specifically provides a kind of pharmaceutical composition that is used for the treatment of fatty liver, and the active component of described pharmaceutical composition comprises one or more the mixture in Fructus Crataegi, Semen Cassiae or Rhizoma Polygoni Cuspidati.
Preferably, in described pharmaceutical composition, the part by weight of described active component is as follows:
Fructus Crataegi 3-50, Semen Cassiae 2-50, Rhizoma Polygoni Cuspidati 5-40;
The part by weight of described active component is more preferably:
Fructus Crataegi 10-50, Semen Cassiae 10-50, Rhizoma Polygoni Cuspidati 5-40;
The part by weight of described active component is more preferably:
Fructus Crataegi 20-40, Semen Cassiae 20-40, Rhizoma Polygoni Cuspidati 10-35;
The part by weight of described active component also can be more preferably:
Fructus Crataegi 25-35, Semen Cassiae 25-35, Rhizoma Polygoni Cuspidati 15-30;
The part by weight of described active component also can most preferably be:
Fructus Crataegi 30, Semen Cassiae 30, Rhizoma Polygoni Cuspidati 20.
Wherein, in described component Fructus Crataegi, effective ingredient comprises Flavonoid substances, as the flavonoid glycoside that contains carbon bond, flavonol and glycoside thereof, dioxygen flavonoid glycoside, polymerization flavonoid.Described component Fructus Crataegi has blood pressure lowering, blood fat reducing, immunomodulating texts.
Effective ingredient in described component Rhizoma Polygoni Cuspidati comprises glycoside (PD), resveratrol, and research shows, glycoside (PD) and resveratrol boil on the nape opposite the mouth are raised rats'liver infringement due to peroxidating Semen Maydis oil and had therapeutical effect.In addition, described component Rhizoma Polygoni Cuspidati also has hepatic cholagogic, blood fat reducing, antiviral, the regulating action of antioxidation and Endocrine system.
In described component Semen Cassiae, effective ingredient comprises emodin (emodin), chrysophanol (chrysophanol), physcione (physcion), obtusin (obtusin), obtusin (obtusifolin) and glycoside thereof, described component Semen Cassiae has blood pressure lowering, blood fat reducing, the effect such as protects the liver.
One of the present invention comparatively in preferred embodiment, described pharmaceutical composition can also comprise one or more the mixture in flavoring agent, excipient, filler, binding agent, disintegrating agent.
Preferably, described flavoring agent is unrestricted, can be selected from one or more in Folium Stevlae Rebaudianae, protein sugar, sucrose, Mel etc.
Described excipient is unrestricted, can be selected from that starch, cellulose family and derivant thereof, dextrin, cyclodextrin and derivant thereof, sucrose, polyvidone series, Polyethylene Glycol are serial, sodium carboxymethyl cellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, Mel, fructose, glucose, mannitol, sorbitol etc.
Described filler is unrestricted, can be selected from one or more in starch and derivant thereof, microcrystalline Cellulose, lactose etc.
Described binding agent is unrestricted, can be selected from one or both in methylcellulose, polyvidone etc.
Described disintegrating agent is unrestricted, can be selected from that low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, microcrystalline Cellulose, cross-linked carboxymethyl cellulose are received, one or more in carboxymethyl starch sodium, agar, starch and derivant thereof etc.
Preferably, above-mentioned excipient, filler, binding agent and disintegrating agent are pharmaceutically spendable reagent.
A second aspect of the present invention also provides a kind of Chinese medicine preparation that contains described Chinese medicine composition, can be prepared into medicinal tea, water decoction, granule, powder, injection, patch, ointment, tablet, pill etc., described Chinese medicine preparation is any one in medicinal tea, water decoction, granule, powder, injection, patch, ointment, tablet, pill.Wherein, also more preferably medicinal tea, water decoction.
A third aspect of the present invention provides a kind of application of aforementioned pharmaceutical compositions, as the ancillary drug for the preparation of acupuncture and moxibustion therapy fatty liver.
Wherein, described acupuncture and moxibustion therapy be included in Tianshu in body, tsu san li, sp 6, rich and prosperous, Taixi, too the acupuncture point such as punching execute pin, preferably, in body, pin is executed in Tianshu, tsu san li, sp 6, rich and prosperous, Taixi, TAICHONG acupoint position.
Wherein, the selected acupuncture point TIANSHU acupoint (ST25) of executing pin belongs to the stomach channel of foot-Yang-ming, is the Mu-front acupoints of large intestine, and people's mechanism of qi is linked up up and down, lifting sink-float, and equal TIANSHU acupoint (ST25) too, main dredging adjusted intestinal internal organs, regulating qi-flowing for activating stagnancy, helped digestion, and is that cave is wanted in reducing abdomen;
The selected acupuncture point sp 6 of executing pin is the meeting of foot three the moon;
The selected acupuncture point of executing pin is rich and prosperous is the luo-connecting point of the stomach channel of foot-Yang-ming, contact the exterior and the interior two warps;
The selected acupuncture point Taixi of executing pin is kidney meridian source points;
The selected acupuncture point of executing pin rushes very much as liver channel of foot-Jueyin source points, and source points is internal organs Primordial Qi infusion, process and stays position only.
When adopting the above-mentioned Tianshu of acupuncture, tsu san li, sp 6, rich and prosperous, Taixi, TAICHONG acupoint position in the present invention, be aided with medicine prepared by the above-mentioned Chinese medicine composition of employing of the present invention, can play invigorating the spleen and regulating the stomach, reduce phlegm and let out effect turbid, smooth the liver and regulate the spleen.
The Chinese medicine preparation that the pharmaceutical composition that contains Fructus Crataegi, Semen Cassiae, Rhizoma Polygoni Cuspidati isoreactivity composition described in the present invention is prepared from, cheap, determined curative effect, safety are good, easy to operation; The above-mentioned Chinese medicine preparation that contains described pharmaceutical composition is combined with acupuncture and moxibustion therapy, forms more advanced, ripe, stable appropriate technology.Wherein, the described fat of dispelling adds taste three taste prescriptions (Fructus Crataegi, Semen Cassiae, Rhizoma Polygoni Cuspidati etc.) in conjunction with acupuncture prescription, have that stable curative effect is definite, method is easy, easily form normalized feature, be convenient in situation of all-level hospitals especially community hospital enforcement of regulations and promote the use, for extensive patients provide honest and clean, just, letter, the medical services of testing.
Specific embodiment
Below in conjunction with specific embodiment, the present invention will be further described, but not as limiting to the invention.
The Chinese medicine ingredients and the effect thereof that in the embodiment of the present invention, adopt are as follows:
Fructus Crataegi: sour, sweet, tepor, returns spleen, stomach, Liver Channel, has the effect of promoting digestion and removing stagnation, promoting blood circulation to remove blood stasis;
Semen Cassiae: sweet, bitter, be slightly cold, return liver, large intestine channel, there is the effect of liver heat removing and eyesight improving, loosening bowel to relieve constipation;
Rhizoma Polygoni Cuspidati: bitter, cold, return liver, gallbladder, lung meridian, there is the effect of receiving clearing away heat-damp and promoting diuresis, blood circulation promoting and blood stasis dispelling.
In embodiments of the invention according to its blood pressure lowering, blood fat reducing, Fructus Crataegi is selected in the effects such as immunomodulating; According to its blood pressure lowering, blood fat reducing, Semen Cassiae is selected in the effect such as protect the liver; According to its hepatic cholagogic, blood fat reducing, antiviral, the regulating action of antioxidation and Endocrine system is selected Rhizoma Polygoni Cuspidati.
embodiment 1
In pharmaceutical composition described in the present embodiment, active component comprises:
Fructus Crataegi 30g, Semen Cassiae 30g, Rhizoma Polygoni Cuspidati 20g;
Described pharmaceutical composition also comprises:
Flavoring agent: Folium Stevlae Rebaudianae 5g.
The Chinese medicine preparation that the pharmaceutical composition that contains above-mentioned active component is prepared into medicinal tea, concrete steps are as follows:
Clean out after 30g Fructus Crataegi, 30g Semen Cassiae and 20g Rhizoma Polygoni Cuspidati, the Chinese medicine after cleaning cleaned, oven dry, co-grinding, sieved, by thick decocting extracting juice, mix with medicated powder, granulate, oven dry, sterilizing, packing obtain required medicinal tea.
Instructions of taking: brew with boiling water every day after meal.
embodiment 2
In pharmaceutical composition described in the present embodiment, active component comprises:
Fructus Crataegi 30g, Semen Cassiae 30g, Rhizoma Polygoni Cuspidati 20g;
Described pharmaceutical composition also comprises:
Flavoring agent: Mel 5g.
The Chinese medicine preparation that the pharmaceutical composition that contains above-mentioned active component is prepared into water decoction, concrete steps are as follows:
Clean out after 30g Fructus Crataegi, 30g Semen Cassiae and 20g Rhizoma Polygoni Cuspidati, the Chinese medicine after cleaning is cleaned, and adopted the water of 300ml to mix, boil rear 20min extracting juice with above-mentioned pharmaceutical composition, 1 dose of every day.
Instructions of taking: take every day for three times, each 100ml, 3 months is 1 course for the treatment of, takes altogether 2 courses for the treatment of.
embodiment 3
In pharmaceutical composition described in the present embodiment, active component comprises:
Fructus Crataegi 50g, Semen Cassiae 20g, Rhizoma Polygoni Cuspidati 20g;
Described pharmaceutical composition also comprises:
Excipient: cyclodextrin 10g, sodium carboxymethyl cellulose 5g;
Filler: starch 8g;
Binding agent: polyvidone 3g;
Disintegrating agent: agar 5g.
The Chinese medicine preparation that the pharmaceutical composition that contains above-mentioned active component is prepared into pill, concrete steps are as follows:
Clean out after 50g Fructus Crataegi, 20g Semen Cassiae and 20g Rhizoma Polygoni Cuspidati, Chinese medicine after cleaning is cleaned, dry after grinding, the fine powder of the pharmaceutical composition of gained and adjuvant (comprising cyclodextrin 10g, sodium carboxymethyl cellulose 5g, starch 8g, polyvidone 3g, agar 5g) are mixed and are had after plastic ball piece, and divided dose is made pill.
embodiment 4
In order to obtain the better therapeutic effect of fatty liver, the Chinese medicine preparation that contains described Chinese medicine composition obtaining in above-described embodiment 1-3 also needs to coordinate acupuncture and moxibustion therapy instrument to use, thereby forms more advanced, ripe, stable, suitable technology.
Use the fat of dispelling described in embodiment 1 described above to add the medicinal tea of taste three taste sides (Fructus Crataegi 30g, Semen Cassiae 30g, Rhizoma Polygoni Cuspidati 20g etc.), brew after meal described medicinal tea every day, and in conjunction with acupuncture and moxibustion therapy 1 week 1 time, be for 10 times a course for the treatment of, totally two courses for the treatment of.
Wherein, acupuncture and moxibustion therapy is specially:
1, prescription: get bilateral Tianshu, tsu san li, sp 6, rich and prosperous, Taixi, Tai Chong.
2, Fang Yi: fatty liver is from dialectical, accumulates in phlegm-damp, stagnation of liver-QI with deficiency of the spleen, that soil is stopped up wood is strongly fragrant the most clinical common, and that chooses the stomach channel of foot-Yang-ming closes cave tsu san li, " close and control interior internal organs ", TIANSHU acupoint (ST25) also belongs to the stomach channel of foot-Yang-ming, is the Mu-front acupoints of large intestine, being that yangming meridian gas is sent out, is just point among the person, as when the world joins, the hinge that lifting is pure and impure, people's mechanism of qi is linked up up and down, lifting sink-float, all TIANSHU acupoint (ST25) too, master dredges and adjusts intestinal internal organs, regulating qi-flowing for activating stagnancy, helps digestion, and is that cave is wanted in reducing abdomen.Sp 6 is the meeting of foot three the moon, rich and prosperous is the luo-connecting point of the stomach channel of foot-Yang-ming, contact the exterior and the interior two warps, for controlling " expectorant ", want cave, Taixi is kidney meridian source points, and too punching is liver channel of foot-Jueyin source points, source points is internal organs Primordial Qi infusion, process and stays position only, we play invigorating the spleen and regulating the stomach in all caves altogether, reduce phlegm that it is turbid to let out, the merit of smooth the liver and regulate the spleen.
3, location:
Tianshu: other two cun of umbilicus.
Tsu san li: patella lower edge, patellar ligament outer concave is sagged 3 cun, the outer horizontal finger place of crista anterior tibiae.
Sp 6: internal ankle height is put 3 cun, facies medialis tibiae trailing edge.
Rich and prosperous: external ankle height is put 8 cun, outside Tiaokou cave 1 cun.
Taixi: in caving between internal ankle height point and heel string.
Too punching: instep, in caving in before first and second metatarsal joint portion.
Fang Yi: invigorating the spleen and regulating the stomach, reduces phlegm that it is turbid to let out, smooth the liver and regulate the spleen.
4, operating procedure:
(1) select position: dorsal position.
(2) select needle set: select disposable acupuncture needle, 0.30mm * 50mm.
(3) sterilization: wipe the acupuncture points on the human body of choosing with 75% cotton ball soaked in alcohol.
(4) inserting needle: clamping method of needle insertion, left hand thumb, food two fingers are held and are pinched sterilization dry cotton ball, clamp needle body lower end, the skin surface position that needle point is fixed on to acupoint, the right hand is held needle handle, makes needle body vertical, when right finger strength presses down, left hand thumb is eaten two fingers and is exerted oneself simultaneously, assists to insert a needle into skin.
(5) angle of needle insertion: all row straight thrusts.
(6) depth of needling: 0.5-1 cun, can grasp flexibly as the case may be.
(7) hand-manipulating of needle with bring about the desired sensation: stick a needle into after the certain depth of acupuncture points on the human body, row is carried wiping, rotating techniques, make it to produce and respond to through gas, be doctor can feel to have under pin Xu and or heavy tight sensation, even patient also can under pin, occur Xiang Ying Acid, fiber crops, swollen, heavily etc. along certain position, to the sensation of certain orientation diffusion conduction.
(8) acusector: connect respectively in bilateral TIANSHU acupoint (ST25) with 2-3V G6805-1 type electric acupuncture apparatus both positive and negative polarity, after energising, patient has abdominal muscles slightly to beat and radiates sense, and this reach therapeutic purposes.
(9) let the acupuncture needle remain at a certain point: 30 minutes.
(10) go out pin: with left hand thumb, forefinger, pin pin hole surrounding skin, it is slightly twisted that the right hand is held pin work, slowly pin carried to subcutaneous, then pin tripped out, and sterilization dry cotton ball is rubbed by pin hole, in case hemorrhage.
In order to verify clinical efficacy and the safety of above-mentioned medicine administered by injection therapeutic alliance, elitely get 60 Patients with Fatty Liver, and be equally divided into medicine administered by injection treatment group, single acupuncture and moxibustion therapy group and blank Zu Sange group.Wherein, medicine administered by injection treatment group adopts above-mentioned medicine administered by injection therapeutic alliance, and single acupuncture and moxibustion therapy group only adopts acupuncture and moxibustion therapy, consistent with described in embodiment 4 of the method for its acupuncture and moxibustion therapy, and blank group is not carried out any treatment or takes any medicine.
In experiment, follow the tracks of medicine administered by injection treatment group, single acupuncture and moxibustion therapy group and blank and organize patient 12 weeks, and follow up a case by regular visits to 1 time for every 4 weeks, after treatment, within the 4th, 8,12 weeks, follow up a case by regular visits to vital sign, physical examination and the laboratory inspection of simultaneously carrying out Patients with Fatty Liver, and liver imaging inspection is carried out in 0,12,24 week after experiment starts respectively, draws survey data.
According to described survey data, can find, in medicine administered by injection treatment group, single acupuncture and moxibustion therapy group, patient's vital sign, physical examination and liver imaging check and are all better than blank group, and every inspection of patient, by the patient who is better than being only suitable for acupuncture and moxibustion therapy, adopts medicine administered by injection therapeutic alliance can effectively treat fatty liver as seen in the medicine administered by injection treatment group of employing medicine administered by injection therapeutic alliance.
In the method for above-mentioned acupuncture and medication in combination fatty liver, can also be aided with diet and exercise prescription, with a nearlyer step, strengthen the effect of medicine administered by injection treatment fatty liver, specific as follows:
Diet prescription card: diet prescription be take balanced diet as object, priority control dinner, diet is quantitative, avoids eating and drinking too much at one meal.Guarantee enough saccharides and appropriate fat, protein, vitamin, wherein saccharide 300g, fatty a small amount of, protein 200g, have enough celluloses and abundant vitamin, smoking cessation, wine.By nutritionist's inquiring gather information record statistics, patient is by the vision score of marking.
Exercise prescription card: adopt the aerobatic exercise of moderate strength.Instruct patient to take exercise by running.5 times weekly, each 1 hour, continuous 3 months.Running velocity is controlled: first jog 5 minutes, then middling speed is run 10 minutes, suitably accelerates every 2 minutes later, until sensation is breathed anxiety, but there is not asthma, uncomfortable in chest, tachycardia phenomenon, during persistent movement to 55 minute, slow down and do restorative jogging, until stop.With diet statistics same method.
In the method for the employing acupuncture and medication in combination fatty liver described in the embodiment of the present invention 4, the selection that adopts is cheap, determined curative effect, three taste drug matchings that safety is good, easy to operation, in conjunction with acupuncture and moxibustion therapy, form more advanced, ripe, stable appropriate technology, at situation of all-level hospitals especially community hospital's enforcement of regulations and popularization, for extensive patients provide honest and clean, just, letter, the medical services of testing.
Based on medicine administered by injection combination, the research of employing Prospective Clinical, and with liver imaging, learn and check (wherein usining CT value as the Main Basis judging) and lab testing double standards, judgement as curative effect, meet the diagnostic criteria of mainstream health care, in conjunction with advanced Fibroscan diagnostic techniques as auxiliary judgment index.On the basis of behavior intervention, only select innovatively drug matching (Fructus Crataegi, Semen Cassiae, Rhizoma Polygoni Cuspidati etc.) in conjunction with acupuncture and moxibustion therapy, and by its clinical practice details, specific, for the treatment of fatty liver disease provides the new technique of standard, and cheap medical expense, the oral and acupuncture manipulation of reduced form, compares with the conventional therapy of other fatty livers, there is social benefit widely, benefit the society and ordinary people.
Above specific embodiments of the invention be have been described in detail, but it is as example, the present invention is not restricted to specific embodiment described above.To those skilled in the art, any equivalent modifications that this practicality is carried out and alternative also all among category of the present invention.Therefore, equalization conversion and the modification done without departing from the spirit and scope of the invention, all should contain within the scope of the invention.
Claims (9)
1. a pharmaceutical composition that is used for the treatment of fatty liver, is characterized in that, the active component in described pharmaceutical composition comprises one or more the mixture in Fructus Crataegi, Semen Cassiae or Rhizoma Polygoni Cuspidati.
2. according to the pharmaceutical composition described in claim 1, it is characterized in that, the part by weight of described active component is as follows:
Fructus Crataegi 3-50, Semen Cassiae 2-50, Rhizoma Polygoni Cuspidati 5-40.
3. according to the pharmaceutical composition described in claim 2, it is characterized in that, the part by weight of described active component is as follows:
Fructus Crataegi 10-50, Semen Cassiae 10-50, Rhizoma Polygoni Cuspidati 5-40.
4. according to the pharmaceutical composition described in claim 3, it is characterized in that, the part by weight of described active component is as follows:
Fructus Crataegi 20-40, Semen Cassiae 20-40, Rhizoma Polygoni Cuspidati 10-35.
5. according to the pharmaceutical composition described in claim 4, it is characterized in that, the part by weight of described active component is as follows:
Fructus Crataegi 25-35, Semen Cassiae 25-35, Rhizoma Polygoni Cuspidati 15-30.
6. according to the pharmaceutical composition described in claim 5, it is characterized in that, the part by weight of described active component is as follows:
Fructus Crataegi 30, Semen Cassiae 30, Rhizoma Polygoni Cuspidati 20.
7. according to the pharmaceutical composition described in any one in claim 1-6, it is characterized in that, described pharmaceutical composition also comprises one or more the mixture in flavoring agent, excipient, filler, binding agent, disintegrating agent.
8. a Chinese medicine preparation that contains pharmaceutical composition described in claim 1, is characterized in that, described Chinese medicine preparation is any one in medicinal tea, water decoction, granule, powder, injection, patch, ointment, tablet, pill.
9. an application for pharmaceutical composition as claimed in claim 1, is characterized in that, for the preparation of the ancillary drug of acupuncture and moxibustion therapy fatty liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410251116.2A CN104161839A (en) | 2014-06-06 | 2014-06-06 | Pharmaceutical composition for treating fatty liver, and traditional Chinese medicine preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410251116.2A CN104161839A (en) | 2014-06-06 | 2014-06-06 | Pharmaceutical composition for treating fatty liver, and traditional Chinese medicine preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104161839A true CN104161839A (en) | 2014-11-26 |
Family
ID=51905964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410251116.2A Pending CN104161839A (en) | 2014-06-06 | 2014-06-06 | Pharmaceutical composition for treating fatty liver, and traditional Chinese medicine preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104161839A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605156A (en) * | 2015-03-05 | 2015-05-13 | 济南康众医药科技开发有限公司 | Raising method for hens capable of producing eggs with effect of treating hypertension |
| CN109350659A (en) * | 2018-12-10 | 2019-02-19 | 成都大学 | A kind of blood lipid-reducing blood sugar-decreasing composition and preparation method thereof, application |
| CN112841362A (en) * | 2021-01-22 | 2021-05-28 | 梁俊雄 | Liver-protecting tea bag and preparation method and application thereof |
| CN115671175A (en) * | 2022-11-14 | 2023-02-03 | 安徽省农业科学院农业工程研究所 | Torreya grandis seed medicinal composition for reducing blood fat and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943762A (en) * | 2006-09-09 | 2007-04-11 | 刘志勇 | A Medicine for treatment of fatty liver and its preparation method |
-
2014
- 2014-06-06 CN CN201410251116.2A patent/CN104161839A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943762A (en) * | 2006-09-09 | 2007-04-11 | 刘志勇 | A Medicine for treatment of fatty liver and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 张霖等: "虎杖苷对非酒精性脂肪肝大鼠保护作用及机制研究", 《陕西中医》, vol. 31, no. 6, 31 December 2010 (2010-12-31), pages 756 - 758 * |
| 陈四清等: "《肝胆病调养食方》", 30 April 2008, article "山楂决明汤", pages: 114 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605156A (en) * | 2015-03-05 | 2015-05-13 | 济南康众医药科技开发有限公司 | Raising method for hens capable of producing eggs with effect of treating hypertension |
| CN109350659A (en) * | 2018-12-10 | 2019-02-19 | 成都大学 | A kind of blood lipid-reducing blood sugar-decreasing composition and preparation method thereof, application |
| CN109350659B (en) * | 2018-12-10 | 2021-09-14 | 成都大学 | Lipid-lowering and blood-sugar-reducing composition, and preparation method and application thereof |
| CN112841362A (en) * | 2021-01-22 | 2021-05-28 | 梁俊雄 | Liver-protecting tea bag and preparation method and application thereof |
| CN115671175A (en) * | 2022-11-14 | 2023-02-03 | 安徽省农业科学院农业工程研究所 | Torreya grandis seed medicinal composition for reducing blood fat and preparation method thereof |
| CN115671175B (en) * | 2022-11-14 | 2024-03-29 | 安徽省农业科学院农业工程研究所 | Chinese torreya seed medicinal composition for reducing blood fat and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988750B (en) | TCM (Traditional Chinese medicine) composition for treating diabetes and preparation method thereof | |
| CN104161839A (en) | Pharmaceutical composition for treating fatty liver, and traditional Chinese medicine preparation thereof | |
| CN104127749A (en) | Traditional Chinese medicament for treating organic phosphorus pesticide poisoning and preparation method thereof | |
| CN100566733C (en) | A kind of external Chinese medicine for the treatment of acne and preparation method thereof | |
| CN102526345B (en) | Chinese medicinal composition for treating hypertension | |
| CN102366541A (en) | Traditional Chinese medicine composition for treatment of diabetes | |
| CN104107321A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN108014183A (en) | A kind of medicine for treating burns, scald, trauma | |
| CN102716334B (en) | Chinese medicinal composition for dispelling the cold and removing stasis | |
| CN106729388A (en) | It is a kind of to treat Chinese medicine preparation of hyperlipidemia and preparation method thereof | |
| CN106490558A (en) | A kind of health-care honey and preparation method thereof | |
| CN103463588B (en) | A kind of Chinese medicine composition for the treatment of sinking of QI of middle-JIAO | |
| CN103599263B (en) | A kind of Chinese medicine for hemorrhoid and preparation method thereof | |
| CN102940820B (en) | Traditional Chinese medicine composition for treating diarrhea | |
| CN104288303A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN103830552A (en) | Traditional Chinese medicine composition for treating Meniere's disease | |
| CN102949571A (en) | Medicine for treating chronic osteomyelitis | |
| CN102580030A (en) | External traditional Chinese medicine composition having effect of reducing blood sugar, preparation prepared from the external traditional Chinese medicine composition, and their preparation method | |
| CN104324341A (en) | Traditional Chinese medicine preparation for treating hyperlipidemia | |
| CN103800838A (en) | Traditional Chinese medicine composition for treating deficiency of the kidney-yin | |
| CN116474058B (en) | Traditional Chinese medicine ointment for treating spleen enlargement | |
| CN102671143B (en) | Parslane herb Chinese medicinal oral liquid for treating dysentery and preparation method for parslane herb Chinese medicinal oral liquid | |
| CN107213283A (en) | A kind of antifatigue, Yin Yang balancing food and medicament dual-purpose Chinese medicine composition and preparation method thereof | |
| CN106729175A (en) | A kind of Chinese medicine preparation for treating hyperlipidemia | |
| CN108310111B (en) | Traditional Chinese medicine formula for benefiting qi and nourishing blood, preparation method and application thereof, medicated diet for benefiting qi and nourishing blood and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20161025 Address after: 200050 Shanghai city Changning District Xianxia Road No. 1111 Applicant after: SHANGHAI TONGREN HOSPITAL Address before: 200336 Shanghai city Changning District Xianxia Road No. 1111 Applicant before: SHANGHAI CHANGNING DISTRICT CENTRAL HOSPITAL |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141126 |